Your browser is no longer supported. Please, upgrade your browser.
IMGN ImmunoGen, Inc. daily Stock Chart
IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own0.60% Shs Outstand147.89M Perf Week-1.19%
Market Cap489.52M Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float147.67M Perf Month32.93%
Income-150.70M PEG- EPS next Q-0.05 Inst Own68.20% Short Float4.86% Perf Quarter16.14%
Sales50.80M P/S9.64 EPS this Y-23.20% Inst Trans-0.23% Short Ratio4.51 Perf Half Y70.62%
Book/sh-0.58 P/B- EPS next Y30.80% ROA-51.90% Target Price4.67 Perf Year-40.25%
Cash/sh1.38 P/C2.39 EPS next 5Y- ROE352.60% 52W Range1.76 - 6.13 Perf YTD-31.04%
Dividend- P/FCF- EPS past 5Y-7.60% ROI- 52W High-45.96% Beta2.21
Dividend %- Quick Ratio- Sales past 5Y-2.30% Gross Margin- 52W Low88.07% ATR0.22
Employees296 Current Ratio2.60 Sales Q/Q22.00% Oper. Margin- RSI (14)58.16 Volatility5.17% 8.56%
OptionableYes Debt/Eq- EPS Q/Q53.90% Profit Margin- Rel Volume0.51 Prev Close3.27
ShortableYes LT Debt/Eq- EarningsNov 01 BMO Payout- Avg Volume1.59M Price3.31
Recom2.40 SMA2012.39% SMA5017.40% SMA20017.08% Volume810,774 Change1.22%
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Feb-01-16Reiterated RBC Capital Mkts Outperform $19 → $18
Nov-25-15Upgrade Jefferies Hold → Buy
Sep-21-15Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-03-15Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-19 12:50AM  Edited Transcript of IMGN earnings conference call or presentation 1-Nov-19 12:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 02:51PM  Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy? Insider Monkey
Nov-06-19 09:01AM  ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting Business Wire -11.65%
Nov-05-19 07:29AM  How Many ImmunoGen, Inc. (NASDAQ:IMGN) Shares Do Institutions Own? Simply Wall St. +22.86%
Nov-04-19 11:54AM  ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally Zacks
09:27AM  Company News for Nov 4, 2019 Zacks
Nov-01-19 07:45AM  ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates Zacks +27.73%
06:30AM  ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results Business Wire
Oct-25-19 10:31AM  ImmunoGen (IMGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-18-19 04:30PM  ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results Business Wire
Sep-30-19 09:49AM  Did ImmunoGen, Inc. (NASDAQ:IMGN) Insiders Buy Up More Shares? Simply Wall St. -11.03%
Sep-29-19 06:01AM  ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO Business Wire
02:31AM  ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO Business Wire
Sep-26-19 01:18PM  Edited Transcript of IMGN earnings conference call or presentation 2-Aug-19 12:00pm GMT Thomson Reuters StreetEvents -6.40%
Sep-17-19 06:30AM  ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO Business Wire -5.31%
Sep-01-19 09:30AM  ImmunoGen (IMGN) Up 18.8% Since Last Earnings Report: Can It Continue? Zacks
Aug-07-19 11:20AM  Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-06-19 06:51AM  Immunogen Inc (IMGN) Q2 2019 Earnings Call Transcript Motley Fool +12.00%
Aug-05-19 10:18AM  ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat Zacks +11.61%
Aug-02-19 03:00PM  What You'll Want to Know About ImmunoGen's Q2 Results Motley Fool
07:55AM  ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:30AM  ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results Business Wire
06:00AM  ImmunoGen, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-19 10:30AM  Earnings Preview: ImmunoGen (IMGN) Q2 Earnings Expected to Decline Zacks +5.86%
Jul-18-19 04:30PM  ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating Results Business Wire
Jul-12-19 08:58AM  Will ImmunoGen Continue to Surge Higher? Zacks
Jun-28-19 02:23PM  Penny Stocks to Buy Using Technical Analysis for July 2019 Investopedia +5.85%
05:36AM  ImmunoGen axes 75% of staff to fund new clinical trial American City Business Journals
Jun-27-19 11:21AM  Heres What Hedge Funds Think About ImmunoGen, Inc. (IMGN) Insider Monkey +5.67%
06:30AM  ImmunoGen Announces Completion of Operational Review Business Wire
Jun-03-19 06:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN ACCESSWIRE
Jun-02-19 09:30AM  Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report? Zacks
May-29-19 04:52PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN GlobeNewswire
May-26-19 05:03PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-22-19 06:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN ACCESSWIRE
11:34AM  Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN Zacks
May-18-19 03:18PM  Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More Benzinga
May-17-19 01:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN ACCESSWIRE
May-16-19 04:35PM  ImmunoGen Plunges as FDA Recommends New Study for Lead Drug Zacks -7.94%
May-15-19 05:43PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN GlobeNewswire -32.06%
05:01PM  ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer Business Wire
04:35PM  Why The Children's Place, Agilent Technologies, and Immunogen Slumped Today Motley Fool
11:42AM  Why ImmunoGen Shares Are Crashing Today Motley Fool
09:31AM  ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug TheStreet.com
08:22AM  ImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug MarketWatch
06:30AM  ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer Business Wire
May-09-19 01:34AM  Edited Transcript of IMGN earnings conference call or presentation 3-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-06-19 09:44AM  ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 Zacks +14.58%
May-05-19 08:16PM  Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy? Insider Monkey
May-03-19 03:08PM  Immunogen Inc (IMGN) Q1 2019 Earnings Call Transcript Motley Fool +15.20%
07:45AM  ImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:36AM  ImmunoGen: 1Q Earnings Snapshot Associated Press
06:30AM  ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results Business Wire
May-02-19 11:44AM  ImmunoGen, Inc. (NASDAQ:IMGN): What Are The Future Prospects? Simply Wall St.
Apr-26-19 10:30AM  Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-18-19 04:30PM  ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results Business Wire
Apr-15-19 01:49PM  ImmunoGen Stock Is in Trouble Going Into Earnings InvestorPlace
Apr-08-19 05:16PM  Here's Why ImmunoGen Tumbled 43% in March Motley Fool
Mar-26-19 03:48PM  Do Directors Own ImmunoGen, Inc. (NASDAQ:IMGN) Shares? Simply Wall St.
Mar-12-19 08:56AM  Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock Zacks
Mar-10-19 09:30AM  ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound? Zacks
Mar-06-19 12:22PM  ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates GuruFocus.com
12:05PM  Four Biotech Stocks Setting The Standard on Wednesday ACCESSWIRE
10:26AM  Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More Zacks
Mar-04-19 11:38PM  Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks Zacks
Mar-02-19 12:48PM  Immunogen Inc (IMGN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-01-19 01:45PM  Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint TheStreet.com -46.82%
12:13PM  Why ImmunoGen Stock Is Crashing Today Motley Fool
08:08AM  Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail American City Business Journals
06:51AM  Immunogen's stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint MarketWatch
06:38AM  ImmunoGen's ovarian cancer drug fails in late-stage study Reuters
06:30AM  ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer Business Wire
Feb-27-19 05:14PM  Why ImmunoGen Tumbled 20.3% Today Motley Fool -20.28%
04:31PM  ImmunoGen Announces Multiple Presentations at AACR Annual Meeting Business Wire
Feb-22-19 07:40AM  Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries New Research Emphasizes Economic Growth GlobeNewswire
Feb-21-19 08:00AM  Healthcare Companies Investors are Watching ACCESSWIRE
Feb-18-19 02:19PM  How ImmunoGen, Inc. (NASDAQ:IMGN) Could Add Value To Your Portfolio Simply Wall St.
Feb-12-19 07:15PM  Edited Transcript of IMGN earnings conference call or presentation 8-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -7.43%
03:58PM  ImmunoGen Still Waiting to Take Its Leap "Forward" Motley Fool
Feb-11-19 09:29AM  ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up Zacks
08:53AM  Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock Zacks
Feb-08-19 09:35PM  ImmunoGen (IMGN) Q4 2018 Earnings Conference Call Transcript Motley Fool +10.31%
07:45AM  ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:47AM  ImmunoGen: 4Q Earnings Snapshot Associated Press
06:30AM  ImmunoGen Reports Recent Progress and 2018 Operating Results Business Wire
Feb-06-19 06:35PM  Why ImmunoGen Jumped Almost 14% Today Motley Fool +13.66%
Feb-01-19 10:30AM  Earnings Preview: ImmunoGen (IMGN) Q4 Earnings Expected to Decline Zacks
Jan-24-19 04:30PM  ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results Business Wire
Jan-18-19 03:00PM  Have Insiders Been Selling ImmunoGen, Inc. (NASDAQ:IMGN) Shares This Year? Simply Wall St.
Jan-09-19 07:39AM  The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-08-19 04:01PM  ImmunoGen Announces Sale of Residual Kadcyla Royalties Business Wire
Jan-07-19 05:20PM  Why ImmunoGen Jumped Today Motley Fool +10.53%
Jan-02-19 08:30AM  ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-26-18 04:18PM  Why ImmunoGen Shot Up 13% Today Motley Fool +13.07%
Dec-17-18 09:52PM  Hedge Funds Are Betting On ImmunoGen, Inc. (IMGN) Insider Monkey
Dec-12-18 07:55AM  Market Trends Toward New Normal in Marriott International, Duke Energy, ImmunoGen, Newell Brands, Vail Resorts, and Fiserv Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-06-18 02:49PM  Roche's Kadcyla Halves Death Risk in Breast Cancer Study Zacks
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
09:30AM  ImmunoGen (IMGN) Down 7.2% Since Last Earnings Report: Can It Rebound? Zacks
Dec-01-18 10:31AM  ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting Business Wire
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gregory Richard J.Executive VP & CSOJan 07Sale5.273,03816,014236,056Jan 08 08:47 AM